Court order extends Teva's asthma treatment exclusivity
Teva benefitted from a US court issuing a temporary restraining order to prevent Actavis Inc. from marketing its generic version of Pulmicort.
The ruling follows Monday's launch of Actavis's generic version of Pulmicort after the court found that it did not infringe the drug's patent.
Under a 2008 agreement with AstraZeneca, Teva has exclusive rights to sell a generic version of Pulimcort. Teva paid AstraZeneca $260 million in 2012 in royalties.
Published by Globes [online], Israel business news - www.globes-online.com - on April 3, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options